Takashi Ushiki

Dr. Takashi Ushiki

Department of Hematology, Niigata University, Niigata, Japan
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Nature Immunology
Verified
Journal Article
Closed access
RDRebecca B Delconte
Rebecca B Delconte
TKTatiana B Kolesnik
Tatiana B Kolesnik
LDLaura F Dagley
Laura F Dagley
JRJai Rautela
Jai Rautela
WSWei Shi
Wei Shi
Nicholas D HuntingtonNicholas D Huntington
Nicholas D Huntington

1 January 2016 in Immunity
Verified
Journal Article
Closed access
RDRebecca B. Delconte
Rebecca B. Delconte
WSWei Shi
Wei Shi
PSPriyanka Sathe
Priyanka Sathe
Takashi UshikiTakashi Ushiki
Takashi Ushiki
CSCyril Seillet
Cyril Seillet
Nicholas D HuntingtonNicholas D Huntington
Nicholas D Huntington

1 December 2010 in Stroke
Verified
Journal Article
Closed access
YFYoushi Fujita
Youshi Fujita
MIMasafumi Ihara
Masafumi Ihara
Takashi UshikiTakashi Ushiki
Takashi Ushiki
HHHideyo Hirai
Hideyo Hirai
SKShinae Kizaka-Kondoh
Shinae Kizaka-Kondoh
RTRyosuke Takahashi
Ryosuke Takahashi
Background and Purpose— To investigate the efficacy of bone marrow mononuclear cell (BMMNC) treatment against ischemic white matter (WM) damage in a hypoperfused brain. Methods— Mice were administered intravenous treatment of vehicle, spleen-derived marrow mononuclear cells (MNCs), or BMMNCs (5×10 6 cells) obtained from enhanced green fluorescent protein transgenic mice 24 hours after bilateral common carotid artery stenosis (BCAS), and then euthanized at either 1 day or 30 days after treatment. Results— Laser speckle perfusion imaging analyses revealed marked recovery of cerebral blood flow (CBF) in the early phase after BMMNC treatment (6 hours after administration), before histological evidence of angiogenesis was assessed by fluorescein-isothiocyanate-dextran perfusion assay. BMMNC treatment induced an increase in vascular endothelial growth factor and Ser1177 phosphorylated endothelial nitric oxide synthase levels in the BCAS-induced mouse brains at 1 day after the treatment. BCAS-induced ischemic WM lesions were significantly improved 30 days after BMMNC treatment despite any evidence of direct structural incorporation of donor BMMNCs into endothelial cells and oligodendrocytes. Instead, enhanced green fluorescent protein-positive donor cells with morphological features of pericytes were observed in the vessel walls. Post-BMMNC administration of an NOS inhibitor abolished early CBF recovery and produced protective effects against ischemic WM damage. Conclusions— BMMNC treatment provides marked protection against ischemic WM damage, enhancing CBF in the early phase and in subsequent angiogenesis, both of which involve nitric oxide synthase activation. These findings suggest promise for the application of BMMNCs for subcortical ischemic vascular dementia.

15 July 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KFKyoko Fuse
Kyoko Fuse
SUShun Uemura
Shun Uemura
STSuguru Tamura
Suguru Tamura
TSTatsuya Suwabe
Tatsuya Suwabe
TKTakayuki Katagiri
Takayuki Katagiri
MMMasayoshi Masuko
Masayoshi Masuko
Although allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a curative therapy for high‐risk acute leukemia (AL), some patients still relapse. Since patients simultaneously have many prognostic factors, difficulties are associated with the construction of a patient‐based prediction algorithm of relapse. The alternating decision tree (ADTree) is a successful classification method that combines decision trees with the predictive accuracy of boosting. It is a component of machine learning (ML) and has the capacity to simultaneously analyze multiple factors. Using ADTree, we attempted to construct a prediction model of leukemia relapse within 1 year of transplantation. With the model of training data (n = 148), prediction accuracy, the AUC of ROC, and the κ‐statistic value were 78.4%, 0.746, and 0.508, respectively. The false positive rate (FPR) of the relapse prediction was as low as 0.134. In an evaluation of the model with validation data (n = 69), prediction accuracy, AUC, and FPR of the relapse prediction were similar at 71.0%, 0.667, and 0.216, respectively. These results suggest that the model is generalized and highly accurate. Furthermore, the output of ADTree may visualize the branch point of treatment. For example, the selection of donor types resulted in different relapse predictions. Therefore, clinicians may change treatment options by referring to the model, thereby improving outcomes. The present results indicate that ML, such as ADTree, will contribute to the decision‐making process in the diversified allo‐HSCT field and be useful for preventing the relapse of leukemia.

1 September 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Takashi UshikiTakashi Ushiki
Takashi Ushiki
Nicholas D HuntingtonNicholas D Huntington
Nicholas D Huntington
SGStefan P. Glaser
Stefan P. Glaser
HKHiu Kiu
Hiu Kiu
AGAngela Georgiou
Angela Georgiou
WAWarren S. Alexander
Warren S. Alexander
The Suppressors of Cytokine Signalling (SOCS) proteins are negative regulators of cytokine signalling required to prevent excess cellular responses. SOCS1 and SOCS3 are essential to prevent inflammatory disease, SOCS1 by attenuating responses to IFNγ and gamma-common (γc) cytokines, and SOCS3 via regulation of G-CSF and IL-6 signalling. SOCS1 and SOCS3 show significant sequence homology and are the only SOCS proteins to possess a KIR domain. The possibility of overlapping or redundant functions was investigated in inflammatory disease via generation of mice lacking both SOCS1 and SOCS3 in hematopoietic cells. Loss of SOCS3 significantly accelerated the pathology and inflammatory disease characteristic of SOCS1 deficiency. We propose a model in which SOCS1 and SOCS3 operate independently to control specific cytokine responses and together modulate the proliferation and activation of lymphoid and myeloid cells to prevent rapid inflammatory disease.

23 December 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKTakahiro Kuchimaru
Takahiro Kuchimaru
TKTetsuya Kadonosono
Tetsuya Kadonosono
STShotaro Tanaka
Shotaro Tanaka
Takashi UshikiTakashi Ushiki
Takashi Ushiki
MHMasahiro Hiraoka
Masahiro Hiraoka
SKShinae Kizaka-Kondoh
Shinae Kizaka-Kondoh
Hypoxia-inducible factor (HIF) functions as a master transcriptional regulator for adaptation to hypoxia by inducing adaptive changes in gene expression for regulation of proliferation, angiogenesis, apoptosis and energy metabolism. Cancers with high expression of the alpha subunit of HIF (HIFα) are often malignant and treatment-resistant. Therefore, the development of a molecular probe that can detect HIF activity has great potential value for monitoring tumor hypoxia. HIF prolyl hydroxylases (HPHDs) act as oxygen sensors that regulate the fate of HIFα protein through its oxygen-dependent degradation (ODD) domain. We constructed a recombinant protein PTD-ODD-HaloTag (POH) that is under the same ODD regulation as HIFα and contains protein transduction domain (PTD) and an interchangeable labeling system. Administration of near-infrared fluorescently labeled POH (POH-N) to mouse models of cancers allowed successful monitoring of HIF-active regions. Immunohistochemical analysis for intratumoral localization of POH probe revealed its specificity to HIF-active cells. Furthermore, lack of the PTD domain or a point mutation in the ODD domain abrogated the specificity of POH-N to HIF-active cells. Overall results indicate that POH is a practical probe specific to HIF-active cell in cancers and suggest its large potential for imaging and targeting of HIF-related diseases.